These comments by the CEO say it all. There is absolutely no doubt more deals are coming.
@While it was occupied with AbbVie’s planned takeover, Shire lost out on one of its deal targets and rivals raised the price for the kinds of biotechs Dr. Ornskov was aiming to buy. As a result, Dr. Ornskov says Shire is now casting a wider net for targets in disorders that may not be truly rare but share certain qualities, such as a limited number of patients treated at very specialized centers. Dr. Ornskov says he is interested in adding drugs and companies that are in Shire’s focus on diseases of the brain, stomach, eyes, hormones and metabolism. He wants to move quickly. “We still have to catch up,” he says. “We did lose six months.”
Shire is trading at 5545p today on the LSE, up 1.8%
@@@Shire : *BERENBERG RESUMES SHIRE WITH 'BUY' - TARGET 6300 PENCE 07/16/2015 | 01:14am US/Eastern
Don;t be fooled by the lack of rumours. I have no doubt further acquisitions will happen. That has been SHPG's modus operandi for many years.
Lots excitements in M&A, do you think we will acquire again, looks like no one is interesting us anymore
SHPG has proven to be quite adept at striking deals that generate solid long-term returns for shareholders, and demonstrated excellent negotiating skills, as evidenced in the large breakup fee they received when ABBV pulled out of the deal to acquire SHPG last year. Whatever happens this time around I have little doubt this company will prosper.
What is increasingly certain is that the status quo is not an option. SHPG will either be acquired or will buy another company. I added a few shares today on this pullback.
Looks like SHPG found a takeover target, and it's a big fat one.
@@LONDON (Reuters) - Pharmaceutical company Shire (SHP.L) is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd (ATLN.VX) Europe's biggest biotech firm, Britain's Sunday Times newspaper reported, citing unnamed sources. An informal approach by Shire was rebuffed several weeks ago, the newspaper said, citing financial industry sources. Shire was willing to pay 160 Swiss francs a share for Actelion, the sources said, a hefty premium to the stock's Friday closing price of 132 francs. Earlier this year, Actelion raised its full-year guidance after strong sales of its new heart and lung drug helped its first-quarter earnings exceed analysts' estimates.
something clearly leaked ... SHPG is considering a 12 billion pound ($18.32 billion) takeover of Actelion Ltd (ATLN.VX) Europe's biggest biotech firm, Britain's Sunday Times newspaper reported, citing unnamed sources. Lets see what transpires this upcoming week